SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is experiencing a significant surge, driven by supportive analyst commentary, including a reiterated 'Buy' rating and an optimistic price target from Jefferies, which underscores its attractive valuation and accelerating monetization across platforms like WhatsApp, Threads, and strategic AI initiatives. The community is actively buying the recent dip, anticipating strong upcoming earnings and further upside potential for the undervalued tech giant, despite some short-term skepticism.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid significant uncertainty surrounding its proposed acquisition of Warner Bros. Discovery's content assets, which faces a competitive counter-offer and a lengthy resolution timeline. This dynamic has created a deeply divided community, with many expressing frustration over the stock's underperformance at multi-month lows, while others view it as a compelling buying opportunity given strong underlying fundamentals and the potential for an expanded content library.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is experiencing heightened investor interest after announcing a strategic non-binding Memorandum of Understanding with the Government of Gujarat and Kaynes SemiCon to establish a post-quantum semiconductor center in India. This development positions the company at the forefront of the rapidly evolving quantum security sector, which is a major talking point at global technology forums. The community is actively discussing the company's growth prospects and the potential for a significant short squeeze.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following Chairman Ryan Cohen's substantial purchase of 1 million shares over two days, reinforcing his belief that CEOs should actively buy their company's stock. This strong insider conviction has energized the community, fueling speculation about a potential short squeeze and a renewed "meme stock" rally, with many expressing excitement and urging others to buy more shares.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold (GLD) is trending due to heightened geopolitical uncertainties and a significant increase in institutional and central bank accumulation, sparking intense community debate. While many investors view gold as a critical safe-haven and a hedge against currency skepticism, others warn that the recent parabolic move reflects a speculative 'mania' vulnerable to a sharp correction. This divergence in sentiment underscores broader concerns about global economic stability and trust in traditional financial systems.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo Holdings Inc. is trending as it commences trading, with community excitement fueled by limited IPO share allocations suggesting high demand. Investors are actively discussing its potential for significant upside, drawing comparisons to other major crypto-related public offerings and highlighting its role in digital asset custody. Many are pointing to its relatively lower IPO share float as a bullish indicator compared to its peers.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is a hot topic as a Massachusetts ruling prohibits a key prediction market competitor from offering sports contracts, with other states considering similar actions, sparking community debate on competition. This development occurs amid concerns over college sports betting integrity and mixed signals from recent state revenue reports, highlighting industry volatility. Investors are keenly watching these regulatory shifts and upcoming Q4 earnings for clarity on market share and profitability.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is drawing significant attention due to its advanced, lightweight, and flexible solar technology, which the community links to Elon Musk's insights on solar-powered AI satellites and evolving space infrastructure needs. Traders are actively discussing the potential for major contracts with "mega-constellations" and defense initiatives like "Golden Dome," anticipating substantial upside given the company's low market capitalization and high short interest.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending following reports of fully driverless robotaxi operations beginning in Austin without a safety monitor, fueling excitement among bulls about its advanced autonomous technology and AI potential. However, the news is met with strong skepticism from bears who question Elon Musk's ambitious timelines and see it as a "pump" before upcoming earnings, maintaining a sharp divide in community sentiment regarding the company's future value.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is actively trending as a key player in deep-sea mining following NOAA's newly streamlined permitting process, under which the company has already filed an expanded application for critical mineral recovery. This regulatory acceleration, coupled with a Congressional hearing featuring TMC's CEO, is driving immense bullish sentiment and calls for a short squeeze, with the community emphasizing the national security implications of securing these essential metals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beam Therapeutics (NASDAQ:BEAM) Insider Sells $644,749.69 in Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 18,629 shares of the firm's stock in a transaction on Thursday, January 15th. The stock was sold at an average...

Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 18,629 shares of the business's stock in a transaction that occurred on Thursday, January 15th. The shares were...

Cathie Wood sends blunt 3-word message on stock outlook in 2026

Cathie Wood is making another bold call on the U.S. economy and stock market.In a 2026 outlook letter published on Jan. 15, the ARK Invest founder and CEO says the U.S. economy is storing up energy...

SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM

SG Americas Securities LLC grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 498.9% during the third quarter, according to its most recent 13F filing with the SEC. The...

Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.1% - Should You Sell?

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.1% - Should You Sell...

BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises

Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.

Beam Therapeutics (NASDAQ:BEAM) Reaches New 1-Year High - Still a Buy?

Beam Therapeutics (NASDAQ:BEAM) Sets New 52-Week High - Time to Buy...

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Time to Buy?

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Still a Buy...

Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?

Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updates and strategic priorities for 2026.read more...

<ul class="summary-bullets"><li>The company expects to submit a biologics license application for risto-cel by year-end 2026.</li><li>Beam ended 2025 with an estimated $1.25 billion in cash, extending its operating runway into 2029.</li><li>Management will further discuss the developments at the J.P. Morgan Healthcare Conference on January 13.</li></ul>Beam Therapeutics Inc. (BEAM) received a boost from William Blair, which reacted&nbsp;positively to the company’s update on its alignment with the U.S. FDA, citing improved visibility into the data required for regulatory submissions. The firm pointed to progress in Beam’s sickle cell therapy risto-cel and its liver-targeted program BEAM-302.William Blair also noted that both programs’ acceptance into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot program could speed development and regulatory review. The brokerage firm reiterated its ‘Outperform’ rating.<h2 class="st-heading-2">Updates on BEAM-302 and Risto-cel</h2>Beam’s update outlined progress across its genetic disease and hematology franchises. The company said it has aligned with the FDA on a potential accelerated approval pathway for BEAM-302 in alpha-1 antitrypsin deficiency (AATD), based on biomarker endpoints. BEAM-302 has shown an in vivo correction of a disease-causing mutation in AATD, and Beam Therapeutics plans to expand patient enrollment to support a future biologics license application (BLA).<a href="https://stocktwits.com/symbol/BEAM">Beam Therapeutics’ stock</a> gained over 28% On Monday afternoon.In hematology, Beam expects to submit a BLA for risto-cel by year-end 2026. The BEACON Phase 1/2 trial is fully enrolled, manufacturing is complete, and recent data continue to show strong efficacy and a predictable manufacturing profile, potentially improving patient experience and treatment center capacity, the company said.Beyond its clinical progress, Beam ended 2025 with an estimated $1.25 billion in cash, extending its operating runway into 2029. This positions the company to fund the anticipated launch of risto-cel and execute pivotal development plans for BEAM-302 without near-term financing risk.Management will further discuss these developments at the J.P. Morgan Healthcare Conference on January 13.<h2 class="st-heading-2">Retail Remains Extremely Bullish</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/BEAM_jpg_e1fba90ff6.webp" alt="BEAM.jpg" width="925" height="99"><figcaption>&nbsp;</figcaption></figure>One user expects a buyout.<stembedurl>https://stocktwits.com/ReadyMate/message/641529269</stembedurl>Another user expects ‘good times’ ahead.<stembedurl>https://stocktwits.com/Millard_Findlemeyer/message/641539254</stembedurl>Over the past year, the stock has gained around 38%.Read also:<a href="https://stocktwits.com/news-articles/markets/equity/why-did-planet-labs-stock-gain-today/cmUad7cR4Ej">&nbsp;Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise 

William Blair welcomed the company’s update on its alignment with the U.S. FDA, saying it gives clear visibility into the data needed for regulatory filings.

Equity

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.01	--	--	N/A
Q3 '25	-$1.04	-$1.10	-5.99%	MISSED
Q2 '25	-$1.11	-$1.00	10.12%	BEAT
Q1 '25	-$1.18	-$1.24	-4.75%	MISSED
Q4 '24	-$1.23	-$1.09	11.27%	BEAT

BEAM
Beam Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BEAM News

BEAMBeam Therapeutics Inc